All Comments by Rachelle Doody
- What About the Brain Shrinkage Seen with Aβ Removal?
- How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
- Drilling Down into the CMS Aduhelm Decision—A Primer
- On Aduhelm, Medicare Agency Gets Pressure From All Sides
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- Davos Alzheimer’s Consortium to Link Global Cohorts
- A New Era of Alzheimer’s Treatment
- Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
- ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab
- Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
- Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
- Metabolic syndrome and dementia risk in a multiethnic elderly cohort.
- Memantine—Good for a Year, But Little Disease Modification
- Cholinesterase Inhibitors Not What They're Cracked Up To Be?